Notice of Ordering Period Extension-Clinical Evaluation of Phenserine Tartrate Extended Controlled Release Tablet

INTRODUCTION

PURSUANT TO RFO SUBPART 5.101- PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.

THIS IS A NOTICE OF INTENT TO AWARD A MODIFICATION UNDER CONTRACT NO. 75N95024D00002 WITH THE UNIVERSITY OF EXETER, UNITED KINGDOM, TO EXTEND THE ORDERING PERIOD BY ONE (1) YEAR.

The National Institute on Aging (NIA) intends to modify the single-award Indefinite Quantity Indefinite Delivery (IDIQ) contract no. 75N95024D00002, Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury. This modification will extend the ordering period as denoted in IDIQ contract clause FAR 52.216-18, Ordering (AUG 2020), to be extended from August 1, 2026, to August 1, 2027.

The extension of the IDIQ ordering period will allow for work, especially initially planned task orders 2 and 3 of the IDIQ Statement of Work to be completed. There are no anticipated follow-on procurements at the writing of this Notice.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

The requirement is classified under NAICS code is 541990: All Other Professional, Scientific, and Technical Services, with a size standard of $19.5M.

REGULATORY AUTHORITY

The resultant modification will include all the applicable provisions and clauses of the RFO initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26.

STATUTORY AUTHORITY

This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO Subpart 6.103-1- Only one responsible source and no other supplies or services will satisfy agency requirements.

DESCRIPTION

Background

There is a significant unmet need for Alzheimer’s disease therapeutics as well as drugs that favorably impact the consequences of brain injury as it can initiate cascades of biological events that may lead to long-term neurodegenerative disorders such as Alzheimer’s disease (AD). One of...